Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 27.05
XON's Cash-to-Debt is ranked lower than
52% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. XON: 27.05 )
Ranked among companies with meaningful Cash-to-Debt only.
XON' s Cash-to-Debt Range Over the Past 10 Years
Min: 9.17  Med: 67.21 Max: 118.37
Current: 27.05
9.17
118.37
Equity-to-Asset 0.59
XON's Equity-to-Asset is ranked lower than
58% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. XON: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
XON' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.12  Med: 0.63 Max: 0.78
Current: 0.59
-2.12
0.78
Piotroski F-Score: 3
Altman Z-Score: 2.66
Beneish M-Score: -3.01
WACC vs ROIC
19.66%
-30.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -65.56
XON's Operating Margin % is ranked higher than
54% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. XON: -65.56 )
Ranked among companies with meaningful Operating Margin % only.
XON' s Operating Margin % Range Over the Past 10 Years
Min: -1028.67  Med: -170.73 Max: -65.56
Current: -65.56
-1028.67
-65.56
Net Margin % -97.74
XON's Net Margin % is ranked lower than
51% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. XON: -97.74 )
Ranked among companies with meaningful Net Margin % only.
XON' s Net Margin % Range Over the Past 10 Years
Min: -1064.27  Med: -138.91 Max: -48.67
Current: -97.74
-1064.27
-48.67
ROE % -29.73
XON's ROE % is ranked higher than
57% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. XON: -29.73 )
Ranked among companies with meaningful ROE % only.
XON' s ROE % Range Over the Past 10 Years
Min: -254.03  Med: -25.77 Max: -15.66
Current: -29.73
-254.03
-15.66
ROA % -18.93
XON's ROA % is ranked higher than
62% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. XON: -18.93 )
Ranked among companies with meaningful ROA % only.
XON' s ROA % Range Over the Past 10 Years
Min: -74.27  Med: -17.49 Max: -10.84
Current: -18.93
-74.27
-10.84
ROC (Joel Greenblatt) % -365.73
XON's ROC (Joel Greenblatt) % is ranked higher than
53% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. XON: -365.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XON' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -460.38  Med: -284.8 Max: -160.11
Current: -365.73
-460.38
-160.11
3-Year Revenue Growth Rate 40.80
XON's 3-Year Revenue Growth Rate is ranked higher than
83% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. XON: 40.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XON' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22  Med: -14.4 Max: 40.8
Current: 40.8
-22
40.8
3-Year EBITDA Growth Rate 20.40
XON's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. XON: 20.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
XON' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.2  Med: -63.4 Max: 20.4
Current: 20.4
-64.2
20.4
3-Year EPS without NRI Growth Rate 4.10
XON's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. XON: 4.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
XON' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.7  Med: -64.7 Max: 4.1
Current: 4.1
-65.7
4.1
GuruFocus has detected 3 Warning Signs with Intrexon Corp $XON.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

XON Guru Trades in Q1 2016

George Soros 57,100 sh (New)
Chase Coleman 2,093,199 sh (+24.97%)
First Eagle Investment 1,187,389 sh (unchged)
Joel Greenblatt 23,282 sh (-59.45%)
» More
Q2 2016

XON Guru Trades in Q2 2016

John Burbank 19,981 sh (New)
Murray Stahl 17,439 sh (New)
Joel Greenblatt 28,320 sh (+21.64%)
Chase Coleman Sold Out
George Soros Sold Out
First Eagle Investment 1,102,004 sh (-7.19%)
» More
Q3 2016

XON Guru Trades in Q3 2016

First Eagle Investment 1,102,004 sh (unchged)
Joel Greenblatt Sold Out
John Burbank Sold Out
Murray Stahl 14,592 sh (-16.33%)
» More
Q4 2016

XON Guru Trades in Q4 2016

Murray Stahl 16,416 sh (+12.50%)
First Eagle Investment 1,102,004 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:BCRX, NAS:ANIP, NAS:BSTC, AMEX:BTX, NAS:CASC, NAS:BDSI, NAS:BMRN » details
Traded in other countries:I5X.Germany,
Intrexon Corp is a synthetic biology company that designs, builds and regulates gene programs using its proprietary and complementary technologies.

Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Top Ranked Articles about Intrexon Corp

Weekly CEO Buys Highlight Insiders invest in Paycom, Intrexon, Akamai, Inovalon, Covanta
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
CEO of Intrexon Invests in Company Insider purchases 34,606 shares
Randal Kirk (Insider Trades), CEO and 10% owner of Intrexon Corp. (XON), purchased 34,606 shares on Dec. 13. The price per share was $28.90 for a total transaction of $1,000,113. Read more...

Ratios

vs
industry
vs
history
PB Ratio 4.25
XON's PB Ratio is ranked lower than
53% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. XON: 4.25 )
Ranked among companies with meaningful PB Ratio only.
XON' s PB Ratio Range Over the Past 10 Years
Min: 3.54  Med: 5.65 Max: 14.93
Current: 4.25
3.54
14.93
PS Ratio 12.49
XON's PS Ratio is ranked higher than
52% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. XON: 12.49 )
Ranked among companies with meaningful PS Ratio only.
XON' s PS Ratio Range Over the Past 10 Years
Min: 5.86  Med: 19.26 Max: 55.07
Current: 12.49
5.86
55.07
Current Ratio 3.33
XON's Current Ratio is ranked lower than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. XON: 3.33 )
Ranked among companies with meaningful Current Ratio only.
XON' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.51 Max: 9.46
Current: 3.33
0.81
9.46
Quick Ratio 3.11
XON's Quick Ratio is ranked lower than
56% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. XON: 3.11 )
Ranked among companies with meaningful Quick Ratio only.
XON' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.13 Max: 9.46
Current: 3.11
0.81
9.46
Days Inventory 141.11
XON's Days Inventory is ranked lower than
53% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. XON: 141.11 )
Ranked among companies with meaningful Days Inventory only.
XON' s Days Inventory Range Over the Past 10 Years
Min: 141.11  Med: 149.45 Max: 244.37
Current: 141.11
141.11
244.37
Days Sales Outstanding 41.36
XON's Days Sales Outstanding is ranked higher than
67% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. XON: 41.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
XON' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.91  Med: 26.75 Max: 73.99
Current: 41.36
0.91
73.99
Days Payable 50.20
XON's Days Payable is ranked lower than
57% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. XON: 50.20 )
Ranked among companies with meaningful Days Payable only.
XON' s Days Payable Range Over the Past 10 Years
Min: 28.36  Med: 84.49 Max: 17536.59
Current: 50.2
28.36
17536.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.90
XON's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. XON: -6.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XON' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -176.2  Med: -167.7 Max: -6.9
Current: -6.9
-176.2
-6.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 13.49
XON's Price-to-Tangible-Book is ranked lower than
84% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. XON: 13.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
XON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.09  Med: 12.26 Max: 16.1
Current: 13.49
7.09
16.1
Price-to-Median-PS-Value 0.65
XON's Price-to-Median-PS-Value is ranked higher than
78% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. XON: 0.65 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XON' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 0.88 Max: 1.87
Current: 0.65
0.55
1.87
Earnings Yield (Greenblatt) % -8.83
XON's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. XON: -8.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XON' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -437.1  Med: 0 Max: 0
Current: -8.83
-437.1
0

More Statistics

Revenue (TTM) (Mil) $190.9
EPS (TTM) $ -1.58
Beta2.28
Short Percentage of Float34.29%
52-Week Range $18.55 - 38.23
Shares Outstanding (Mil)118.73
» More Articles for XON

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight Dec 19 2016 
CEO of Intrexon Invests in Company Dec 15 2016 
The Emperor Has No Clothes Aug 17 2016 
CEO and Part Owner of JMP Group Invests in Company Jan 20 2016 
Intrexon Corp is expanding his business Jun 25 2015 
Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 

More From Other Websites
Cramer's lightning round: Stick with this 'terrific' defense play Mar 28 2017
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in... Mar 27 2017
ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications Mar 27 2017
Jorge Espanha Appointed General Manager of Oxitec do Brasil Mar 17 2017
AquaBounty Technologies, Inc. Results for the year ended December 31, 2016 Mar 16 2017
Intrexon Corp. breached its 50 day moving average in a Bearish Manner : XON-US : March 14, 2017 Mar 14 2017
Intrexon executive out less than a year after joining the company Mar 13 2017
INTREXON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Mar 10 2017
Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to... Mar 10 2017
Fibrocell Reports 2016 Financial Results and Recent Operational Highlights Mar 09 2017
Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial... Mar 07 2017
Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million Mar 07 2017
INTREXON CORP Financials Mar 07 2017
Intrexon Corp. :XON-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Shell Deal Hands Biggest U.S. Oil Refinery to Saudi Aramco Mar 07 2017
Andy Bass to Lead Biological & Popular Culture, Intrexon's Consumer Sector Mar 06 2017
Intrexon (XON) Q4 Loss Wider than Expected, Revenues Lag Mar 03 2017
Intrexon Corp. breached its 50 day moving average in a Bullish Manner : XON-US : March 3, 2017 Mar 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)